David M. Stack Sells 12,849 Shares of Pacira Biosciences Inc (NASDAQ:PCRX) Stock

Pacira Biosciences Inc (NASDAQ:PCRX) CEO David M. Stack sold 12,849 shares of Pacira Biosciences stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $39.15, for a total transaction of $503,038.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

David M. Stack also recently made the following trade(s):

  • On Monday, July 8th, David M. Stack sold 13,115 shares of Pacira Biosciences stock. The shares were sold at an average price of $42.88, for a total transaction of $562,371.20.
  • On Tuesday, June 4th, David M. Stack sold 12,385 shares of Pacira Biosciences stock. The shares were sold at an average price of $42.91, for a total transaction of $531,440.35.

PCRX stock opened at $38.22 on Friday. The company’s 50 day moving average price is $42.22 and its 200 day moving average price is $41.34. The company has a debt-to-equity ratio of 0.99, a quick ratio of 7.83 and a current ratio of 4.75. Pacira Biosciences Inc has a fifty-two week low of $35.07 and a fifty-two week high of $55.00. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 59.39, a PEG ratio of 1.76 and a beta of 1.15.

Pacira Biosciences (NASDAQ:PCRX) last released its earnings results on Thursday, August 8th. The company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.27. The firm had revenue of $102.60 million for the quarter, compared to analyst estimates of $99.92 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 earnings per share. Equities analysts forecast that Pacira Biosciences Inc will post 0.66 EPS for the current fiscal year.

PCRX has been the subject of several recent research reports. BidaskClub lowered shares of Pacira Biosciences from a “hold” rating to a “sell” rating in a report on Friday. Mizuho upgraded shares of Pacira Biosciences from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $29.00 to $38.00 in a research note on Monday, May 6th. Wedbush set a $85.00 target price on shares of Pacira Biosciences and gave the stock a “buy” rating in a research note on Friday, June 28th. Stifel Nicolaus set a $42.00 target price on shares of Pacira Biosciences and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, BMO Capital Markets cut their target price on shares of Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating on the stock in a research note on Friday, August 9th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $54.13.

Institutional investors have recently made changes to their positions in the business. HM Payson & Co. purchased a new position in Pacira Biosciences in the second quarter valued at approximately $39,000. C M Bidwell & Associates Ltd. purchased a new position in Pacira Biosciences in the second quarter valued at approximately $44,000. Tower Research Capital LLC TRC increased its stake in Pacira Biosciences by 414.7% in the second quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after purchasing an additional 1,157 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in Pacira Biosciences in the first quarter valued at approximately $65,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Pacira Biosciences in the second quarter valued at approximately $71,000. Institutional investors own 99.89% of the company’s stock.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: Put Option

Insider Buying and Selling by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.